SpIntellx, Inc., a computational and systems pathology company harnessing the computational power of unbiased spatial analytics and explainable artificial intelligence (xAI) technologies to offer proprietary software products and services for analyzing pathology tissue sections, and CellNetix Pathology & Laboratories, a rapidly growing pathology laboratory company providing comprehensive subspecialty clinical and anatomic pathology services in the Pacific Northwest, today announced a collaboration to validate the SpIntellx HistoMaprTM – Breast platform. HistoMapr–Breast is the first of planned spatial analytics and xAI pathologist guides designed to: triage the case workload to direct the most difficult and borderline cases to subspecialists; perform retroactive quality assurance to improve pathologists’ accuracy and efficiency and reduce intra- and inter-pathologist discordance; provide transparent xAI guidance that explains why the algorithms made a specific recommendation; and facilitate standardized reporting in real time.
“We are thrilled to be working with SpIntellx in further developing and validating HistoMapr and the use of explainable artificial intelligence (xAI) in the practice of pathology,” remarked Dr. Dominique Coco, lead project pathologist with CellNetix Pathology & Laboratories. “We see great potential in xAI which could rapidly reshape how we practice pathology.”
“We will be working closely with CellNetix Pathology & Laboratories to complete the validation of HistoMapr-Breast as the final step in our commercialization process. We are delighted to be partnering with CellNetix,” stated SpIntellx co-founder and CEO, S. Chakra Chennubhotla, PhD.